CoDeveloping biomedical products with a French company to fight pandemics.
A collaboration between Ruhvenile Biomedical, India, and RNA Smart Health, Paris, France, aims to develop RNA-based therapeutics to combat COVID-19.
The company benefits from 10 years of experience with cutting-edge technologies and know-how in Genetic Code Expansion and gene editing (CRISPR-Cas9).
In this collaboration, engineered antibodies targeting neurodegenerative diseases will be developed using genetic editing techniques. These novel-engineered antibodies will ultimately be translated into diagnostic kits, research resources, and clinical therapeutics.
” engineered antibodies targeting neurodegenerative diseases will be developed using genetic editing techniques”
We will also check the following:
- Comprehensive short- and long-term follow-up of COVID-19-associated neurological symptoms in patients with COVID-19 infection.
- Next-Generation, Multi-function antibodies to target enveloped viruses.